For UK Healthcare Professionals
Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.

For more information about Vencarm XL (venlafaxine), please see the prescribing information.

About Vencarm XL

Welcome to

Vencarm XL is a prolonged-release capsule of venlafaxine indicated for the:1

  • Treatment of major depressive episodes

  • Prevention of recurrence of major depressive episodes

  • Treatment of generalised anxiety disorder

  • Treatment of social anxiety disorder

  • Treatment of panic disorder, with or without agoraphobia

Available as:

  • 37.5mg prolonged-release capsules

  • 75mg prolonged-release capsules

  • 150mg prolonged-release capsules

  • 225mg prolonged-release capsules

Vencarm XL is bioequivalent to the originator EFEXOR XL (venlafaxine prolonged-release capsules) (Pfizer Ltd)2

Vencarm XL could offer cost savings across all strengths to your practice and Integrated Care System/Board (ICS/B)³.

Venlafaxine 37.5mg and 150mg prolonged-release capsules are in category C of the UK Drug Tariff, 75mg and 225mg prolonged release capsules are Category M products within the UK Drug tariff. Venlafaxine modified-release tablets across all strengths are in category C of the UK Drug Tariff.³

Vencarm XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition:

  • Full range of strengths available for Vencarm XL;

  • Available from mainline wholesalers;

  • High level of stockholdings;

  • Bioequivalent to the originator brand;²
  • Price guaranteed*

*No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2026 VPAG review. Venlafaxine 75 mg and 225mg prolonged release capsules are category M products, category M is defined as drugs which are readily available as generic.3 A products reimbursement price is calculated by the Department of Health and Social Care (DHSC) based on information submitted by manufacturers. All other strengths of Venlafaxine prolonged release tablets and capsules are Category C products. These are defined as not being readily available as a generic and the reimbursement price being based on a particular brand/supplier often the brand originator or market leader.
References 1) Vencarm XL SmPCs. 2) Data on file. 1010067149 v 6.0 September 2023. 3) February 2024 UK Drug Tariff.


For further information please call: 01730 231148,
email: [email protected] or visit
Revision reference – Vencarm XL_12_01.02.24

More products available
in this range:
Click to view their
individual websites